Not FDA-approved2Evidence: Smaller human trialsHormones · Gut and digestion

Ipamorelin2

Also called Ipamorelin acetate1

Key takeaway

Ipamorelin is a lab-made five-amino-acid peptide that mimics ghrelin, a hormone that stimulates growth hormone release. It was first synthesized by Novo Nordisk researchers in the mid-1990s.3 It is not an FDA-approved drug. FDA’s 2024 evaluation found that neither ipamorelin nor ipamorelin acetate is a component of an FDA-approved drug.3 Its main human study, a small randomized trial after bowel surgery, did not show a statistically significant benefit, and FDA concluded the evidence for growth hormone deficiency or recovery after surgery is limited.3 FDA staff recommended against adding ipamorelin to the list of substances pharmacies may use in compounding, and ipamorelin is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.3,6

Ipamorelin at a glance

What it isA synthetic peptide of five amino acids, including unnatural ones, that acts as a ghrelin mimetic and stimulates growth hormone release.3
FDA statusNot FDA-approved. FDA staff recommended in 2024 against adding either form to the 503A compounding list, and FDA lists ipamorelin acetate among compounding substances that may present significant safety risks under its 503B interim policy.1,3
Human evidenceOne small randomized, placebo-controlled trial after bowel surgery that found no statistically significant benefit, and a placebo-controlled pharmacology study in 48 healthy men.3
Sport statusFDA’s 2024 briefing notes that ipamorelin is on the World Anti-Doping Agency’s prohibited list under section S2.4.3
Evidence strengthSmaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned

What is ipamorelin?

Ipamorelin is a synthetic pentapeptide, a chain of five amino acids that includes unnatural amino acids. FDA describes it as a ghrelin mimetic, meaning it imitates ghrelin, a hormone that stimulates growth hormone release.3

FDA’s briefing states that Novo Nordisk researchers first synthesized it in the mid-1990s and that it was first described in the literature in 1998. It exists as a free base and as an acetate salt, which FDA treats as different substances.3

FDA found it marketed by wellness clinics and medical spas for uses such as weight loss, anti-aging, sleep and bodybuilding, sometimes combined with other peptides such as sermorelin. Outsourcing facilities reported compounding it from 2017 to 2020.3

How is ipamorelin thought to work?

FDA’s briefing describes ipamorelin as acting mainly through ghrelin receptors in the brain and on pituitary cells to stimulate growth hormone release.3

FDA notes that peptides with unnatural amino acids are harder to characterize, and that impurities or clumping of peptide chains could make immune reactions more likely.3

What do human studies show?

FDA found one clinical study of ipamorelin’s effectiveness: a Phase 2, randomized, double-blind, placebo-controlled trial in 117 hospitalized adults having bowel surgery, published in 2014, in which 114 received ipamorelin or placebo.3

The median time to the first tolerated meal was 25.3 hours with ipamorelin and 32.6 hours with placebo, a difference the study reported as not statistically significant. Secondary measures of bowel recovery and hospital stay also showed no differences.3

FDA notes that adverse events in that trial included low potassium, insomnia, high blood sugar, nausea, vomiting, abdominal swelling and two deaths, and that it is unclear whether the deaths were related to ipamorelin. FDA cites a later report that development for this use was discontinued.3

The study cited to FDA for growth hormone deficiency was a randomized, placebo-controlled pharmacology study in 48 healthy men that reported no effectiveness data. FDA found no other publications evaluating ipamorelin for growth hormone deficiency.3

What the evidence base contains

  • Controlled human trial A Phase 2, multicenter, randomized, double-blind, placebo-controlled trial in 117 hospitalized adults after bowel resection, of whom 114 received study drug, published in 2014. FDA reports that its main result was not statistically significant.3
  • Controlled human trial A randomized, placebo-controlled pharmacology study in 48 healthy men that measured blood levels and growth hormone responses. FDA notes it reported no effectiveness data.3

Evidence-strength label: Smaller controlled human trials. How this label is assigned

Is ipamorelin FDA-approved?

No. FDA’s evaluation, dated August 19, 2024, states that neither ipamorelin (free base) nor ipamorelin acetate is a component of an FDA-approved drug, and that there is no United States Pharmacopeia monograph for either.3

FDA staff evaluated both forms for the 503A bulks list, the list of substances that pharmacies may use in compounding, for growth hormone deficiency and recovery of bowel function after surgery. They concluded that the balance of criteria weighs against adding either form, citing poor characterization data, limited evidence of effectiveness and safety concerns.3

A Federal Register notice announced that FDA’s Pharmacy Compounding Advisory Committee would discuss ipamorelin-related substances at its October 29, 2024 meeting. FDA’s briefing states that FDA will not issue a final determination until the committee’s input has been considered and all reviews are finalized.3,4

FDA’s compounding safety-risk page, current as of April 22, 2026, lists ipamorelin acetate in category 2 under the 503B interim policy since September 29, 2023, and among substances whose nominations were withdrawn. It cites possible immune reactions and a published report of serious adverse events, including death.1

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Ipamorelin is not among them.5,6

FDA’s briefing also notes that Australia’s medicines scheduling committee added ipamorelin to its Poisons Standard as a performance and image enhancing drug. None of the sources reviewed here reports an approval of ipamorelin in any country.3

Timeline

  1. Ipamorelin is first described in the scientific literature, according to FDA’s briefing.3
  2. Ipamorelin acetate is placed in category 2 under FDA’s 503B interim policy, according to FDA’s compounding safety-risk page.1
  3. FDA staff date their evaluation recommending against adding ipamorelin to the 503A bulks list.3
  4. A Federal Register notice announces the October 29, 2024 advisory-committee meeting that will discuss ipamorelin.4
  5. FDA’s Pharmacy Compounding Advisory Committee meets to discuss ipamorelin-related substances.3,4
  6. FDA’s compounding safety-risk page, as last updated, lists ipamorelin acetate in category 2 under the 503B interim policy and among withdrawn nominations.1

What is still unknown?

Whether ipamorelin has any clinical benefit: FDA found the evidence for growth hormone deficiency and recovery after surgery limited.3

Its safety in the compounded form that was nominated, for which FDA says there are no safety data.3

What is in products sold under the name: FDA notes that the free base and acetate forms are different substances and that the nominations did not make clear which one was proposed.3

FDA’s final decision on the 503A list, which was not part of the sources reviewed through November 14, 2026.1,3

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Ipamorelin: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Ipamorelin are the records PeptideScanner has selected and published, not every registration or paper about Ipamorelin. A daily check adds newly updated registrations and newly indexed papers that pass the publication checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

Not FDA-approved; named as an unapproved new drug in a federal enforcement case. FDA staff recommended in 2024 against adding ipamorelin or ipamorelin acetate to the 503A compounding list, and FDA lists ipamorelin acetate among substances that may present significant safety risks. Ipamorelin is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.↗↗↗↗

Status sources checked through July 22, 2026. See status sources and coverage →

What do the reviewed human studies say?

Human evidence reviewed September 15, 2026 · Review version 2.

Review source snapshots checked September 15, 2026 · Integrity checked September 15, 2026.

Four selected reports cover intravenous ipamorelin in bowel-surgery patients and healthy volunteers, plus analytical reports involving nasal exposure. These different purposes and routes do not establish benefit for other proposed uses.↗↗↗↗

What the reviewed sources report

The postoperative-ileus trial found no statistically significant improvement in its key or secondary efficacy analyses. The healthy-volunteer study measured growth hormone responses, which do not establish clinical benefit. The additional urine studies concern detection and receptor binding, not therapeutic benefit.↗↗↗↗

What remains unresolved?

  • Are there adequately controlled studies for proposed uses outside postoperative bowel recovery?↗↗
  • How do route, formulation and follow-up affect what can be concluded about harms?↗↗

Read study designs, results, limitations, and sources →

What does the official evidence assessment say?

FDA assessment dated August 19, 2024 · Read September 15, 2026 · Preserved version 1

FDA's evaluation of ipamorelin free base and acetate for growth hormone deficiency and postoperative ileus, prepared for the October 2024 advisory meeting. It is a dated agency assessment, not a final compounding determination. FDA document ↗

Identity and approval scope

FDA distinguishes free base from acetate and states that neither was a component of an FDA-approved drug at the time of its assessment. Study reports did not always identify the form administered. FDA pp. 6, 35 ↗

What did FDA find about effectiveness?

FDA found insufficient evidence supporting the evaluated uses and no clinical effectiveness or safety data for the proposed subcutaneous route. Intravenous postoperative findings do not establish subcutaneous effectiveness. FDA pp. 42, 43 ↗

Serious events require explicit context

FDA reports two deaths among ipamorelin-treated postoperative patients, alongside higher rates of hypokalemia and hyperglycemia. The agency explicitly states that whether the deaths were related to ipamorelin is unclear. FDA pp. 37, 42 ↗

Scope, source pin and remaining work

This summarizes the agency's dated assessment. It is not an independent claim that no evidence exists worldwide or that the briefing is a final regulatory decision. Newer reports and formulation identities require separate screening.

Source: FDA evaluation of ipamorelin-related bulk substances, August 19, 2024. SHA-256: 751d3a46471342fd83a14540bd4ed7fb2f802df89c71f1792c4d0abb2b7c671e.

Open versioned assessment data →

Reviews summarize selected studies; their scope and limitations are shown above.

Read the full Human Evidence Review

Supervised synthesis

What do selected human studies report about Ipamorelin?

Manually reviewed September 15, 2026 · version 2

Browse all Human Evidence Reviews · Open preserved synthesis version 2 →

Four selected reports cover intravenous ipamorelin in bowel-surgery patients and healthy volunteers, plus analytical reports involving nasal exposure. These different purposes and routes do not establish benefit for other proposed uses.1234

Bottom line from this bounded source set

The postoperative-ileus trial found no statistically significant improvement in its key or secondary efficacy analyses. The healthy-volunteer study measured growth hormone responses, which do not establish clinical benefit. The additional urine studies concern detection and receptor binding, not therapeutic benefit.1234

Reviewed study record

Postoperative ileus: a placebo-controlled phase 2 trial

Design

A multicenter blinded randomized placebo-controlled study assessed recovery after bowel resection.1

Population

The trial enrolled 117 adults; 114 were included in its safety and modified intent-to-treat populations.1

Outcomes reported

Time to a tolerated solid meal was not significantly different between groups. Treatment-emergent adverse events occurred in 87.5% with ipamorelin and 94.8% with placebo.1

Limitations

The study was small and included varied underlying conditions. A nonsignificant result does not prove equivalence, and these postoperative findings do not establish safety for other uses or routes.1

Reviewed study record

Healthy-volunteer pharmacokinetics and hormone response

Design

An escalating-exposure study modeled drug concentrations and growth hormone responses.2

Population

The report describes eight healthy men at each of five exposure levels.2

Outcomes reported

The study observed an episode of growth hormone release and substantial between-person variability in pharmacodynamic responses.2

Limitations

The endpoints were pharmacology and hormone measurements, not clinical benefits. The abstract does not provide enough adverse-event detail for a safety conclusion.2

Reviewed study record

Analytical study after nasal exposure

Design

An analytical study examined urine collected over two days after administration of several growth-hormone-releasing peptides.3

Population

The report states that each compound was administered to one volunteer.3

Outcomes reported

The study identified ipamorelin and metabolites in urine using mass spectrometry.3

Limitations

This establishes an analytical human-exposure report, not evidence of therapeutic efficacy or adequately assessed safety. Results for the other compounds cannot be transferred to ipamorelin.3

Reviewed study record

Receptor assay using excretion-study samples

Design

Researchers tested receptor binding of peptides and metabolites and applied the assay to urine from nasal-administration studies.4

Population

The abstract does not state the participant count or establish whether these samples overlap the earlier analytical report.4

Outcomes reported

The assay detected receptor-binding activity in excreted urine from studies that included ipamorelin.4

Limitations

Receptor binding in a sample is not a patient health outcome. Cohort overlap remains unresolved, so this report should not be counted as independent clinical replication.4

Reviewed source set

  1. PubMed · 25331030Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. ↗PubMed PMID 25331030 · EFetch XML reviewed 2026-09-15 · payload SHA-256 f433760c65427acf99c62a5d9a61fcfba84fbb3c078f210883e5bf48385c2048
    No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1007/s00384-014-2030-8. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
  2. PubMed · 10496658Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. ↗PubMed PMID 10496658 · EFetch XML reviewed 2026-09-15 · payload SHA-256 cf3430bee6cf65464ccd2269b6bd37fdc455da5da1fca8b06c461771b6d0a855
    No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1023/a:1018955126402. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
  3. PubMed · 25869809Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin. ↗PubMed PMID 25869809 · EFetch XML reviewed 2026-09-15 · payload SHA-256 55d9efcb0b6ffc6c0ba5a8e2da173d85c80f4b04e5ccae9fce0baa45db0204c6
    No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1002/dta.1787. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
  4. PubMed · 26811125Structure-activity relationship for peptídic growth hormone secretagogues. ↗PubMed PMID 26811125 · EFetch XML reviewed 2026-09-15 · payload SHA-256 892d6eccb0fc12b08c2ed8ee2f594425735ea479769ee1dc85e92943908a5af4
    No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1002/dta.1947. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
Official-source readings

Official-source update

Reviewed 2026-09-19 · Preserved version 1

The pharmacology study does not establish chronic treatment benefit

FDA’s October 2024 briefing describes intravenous pharmacology in healthy male volunteers. It found no corresponding pharmacokinetic or pharmacodynamic evidence for the proposed subcutaneous route. FDA PDF pp. 35 ↗

More findings and the sources behind them

Selected FDA advisory-briefing sections, not a final agency ruling. The source date identifies the committee meeting (July 23–24 for the 2026 packages), not a new approval or final decision.

The surgical trial studied a different clinical setting

The safety discussion concerns hospitalized adults after bowel surgery, not a general wellness population or chronic growth-hormone-deficiency treatment. The formulation was not fully specified in the clinical report. FDA PDF pp. 35, 37 ↗

Serious events were reported, with causality unresolved

FDA describes serious postoperative events and two deaths among ipamorelin-treated participants. It explicitly states that their relationship to ipamorelin was unclear, while considering the overall findings a safety concern. FDA PDF pp. 37 ↗

Product quality is part of the uncertainty

FDA raised questions about impurities, aggregates, endotoxins and immunogenicity for the nominated substances. Its staff recommendation against 503A-list inclusion is a pre-decision assessment, not itself a final agency ruling. FDA PDF pp. 1, 40 ↗

What remains to be checked

  • Check subsequent advisory records and any final FDA action separately from the staff briefing.
  • Retrieve and appraise the original human reports and proposed formulation or route; agency search findings are dated and do not establish a complete worldwide literature review.
Source dates and review coverage

PDF citations use file page numbers. Named webpage sections and registry fields identify the portions read. These are selected readings, not complete source coverage.

  • FDA ipamorelin briefing for the October 2024 advisory meeting ↗

    Source dated 2024-10-29; retrieved 2026-09-19.

    • The pharmacology study does not establish chronic treatment benefit · PDF pp. 35 of 55
    • The surgical trial studied a different clinical setting · PDF pp. 35, 37 of 55
    • Serious events were reported, with causality unresolved · PDF pp. 37 of 55
    • Product quality is part of the uncertainty · PDF pp. 1, 40 of 55

    SHA-256: 751d3a46471342fd83a14540bd4ed7fb2f802df89c71f1792c4d0abb2b7c671e

Open versioned findings and source records →

Research coverage and study families

Search and screening record checked 2026-09-15. Counts describe records, not independent trials. Full-text appraisal is separate from an abstract review.

Open machine-readable coverage and record decisions →

PubMed search

Original human ipamorelin administration and administration-sample reports, including pharmacokinetics. Reviews, other compounds, preclinical and sample-only method studies are separate evidence categories.

50 retrieved · 4 included · 45 excluded · 1 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

"ipamorelin"[Title/Abstract]

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T11:57:46.036747+00:00 · HTTP 200 · SHA-256 57ffc7f7d59fa7e0830c4758d28e1f810343ba293aa4338065d96f8c8560cff5.

  • Open the source endpoint ↗

    Retrieved 2026-09-15T11:57:47.168729+00:00 · HTTP 200 · SHA-256 b373d598fd6614f464aba809721936f42cab2a2e863a30a6e4201ab613590c57.

  • Eligibility decisions use titles and abstracts from the pinned PubMed results; unavailable details remain unresolved rather than inferred.
  • Full-text appraisal, study-family reconciliation, registry history and broader alias/jurisdiction searches remain separate open work.

Showing 25 of 50 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. PubMed 26811125 — include: Original human administration or analysis of administration-study samples; analytical exposures do not establish therapeutic benefit or safety.
  2. PubMed 25869809 — include: Original human administration or analysis of administration-study samples; analytical exposures do not establish therapeutic benefit or safety.
  3. PubMed 25331030 — include: Original human administration or analysis of administration-study samples; analytical exposures do not establish therapeutic benefit or safety. Study families: NCT00672074.
  4. PubMed 10496658 — include: Original human administration or analysis of administration-study samples; analytical exposures do not establish therapeutic benefit or safety. Study families: ipamorelin-1999-pharmacology.
  5. PubMed 26472487 — unresolved: The abstract describes urine containing ipamorelin but does not establish whether the samples followed human administration or were fortified; full text is needed.
  6. PubMed 42578445 — exclude: Review of existing peptide evidence; no new ipamorelin human administration reported.
  7. PubMed 42395176 — exclude: Review of existing peptide evidence; no new ipamorelin human administration reported.
  8. PubMed 42160466 — exclude: Review of existing peptide evidence; no new ipamorelin human administration reported.
  9. PubMed 42123471 — exclude: Review of existing peptide evidence; no new ipamorelin human administration reported.
  10. PubMed 42021992 — exclude: Review of existing peptide evidence; no new ipamorelin human administration reported.
  11. PubMed 41966639 — exclude: Review of existing peptide evidence; no new ipamorelin human administration reported.
  12. PubMed 41880199 — exclude: Review of existing peptide evidence; no new ipamorelin human administration reported.
  13. PubMed 41490200 — exclude: Review of existing peptide evidence; no new ipamorelin human administration reported.
  14. PubMed 41476424 — exclude: Review of existing peptide evidence; no new ipamorelin human administration reported.
  15. PubMed 39043357 — exclude: Animal, cell or compound-development study, outside the human-administration subset.
  16. PubMed 38996787 — exclude: Animal, cell or compound-development study, outside the human-administration subset.
  17. PubMed 32801950 — exclude: Animal, cell or compound-development study, outside the human-administration subset.
  18. PubMed 32257855 — exclude: Review of existing peptide evidence; no new ipamorelin human administration reported.
  19. PubMed 30282322 — exclude: Animal, cell or compound-development study, outside the human-administration subset.
  20. PubMed 30168238 — exclude: Animal, cell or compound-development study, outside the human-administration subset.
  21. PubMed 30136411 — exclude: Product/sample-method or nonhuman analytical research; inspected abstracts do not report human ipamorelin administration. Other peptides used in human validation are separate exposures.
  22. PubMed 29864719 — exclude: Product/sample-method or nonhuman analytical research; inspected abstracts do not report human ipamorelin administration. Other peptides used in human validation are separate exposures.
  23. PubMed 27497113 — exclude: Product/sample-method or nonhuman analytical research; inspected abstracts do not report human ipamorelin administration. Other peptides used in human validation are separate exposures.
  24. PubMed 26578461 — exclude: Product/sample-method or nonhuman analytical research; inspected abstracts do not report human ipamorelin administration. Other peptides used in human validation are separate exposures.
  25. PubMed 24574167 — exclude: Product/sample-method or nonhuman analytical research; inspected abstracts do not report human ipamorelin administration. Other peptides used in human validation are separate exposures.

ClinicalTrials.gov search

ClinicalTrials.gov API v2 identity-name search, complete retrieved records. Includes protocols, extensions, combinations and expanded access; these are not all efficacy trials or published outcomes.

3 retrieved · 2 included · 0 excluded · 1 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

ipamorelin

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T08:28:06.298889+00:00 · HTTP 200 · SHA-256 0fdd8c4b8183fd009c884c24c46ccfc184f9a7faf2278dadb8ffa5931c1e4edf.

  • Registry identity screening is distinct from appraisal of posted results, protocol history and publication linkage.
  • Other registries and unregistered studies are outside this search.

Showing 3 of 3 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. ClinicalTrials.gov NCT01280344 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT01280344.
  2. ClinicalTrials.gov NCT00672074 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT00672074.
  3. ClinicalTrials.gov NCT07717866 — unresolved: Broad multicomponent protocol lists nonspecific physiological supplementation; ipamorelin exposure is not resolved.

FDA search

Exact active-ingredient terms in the openFDA Drugs@FDA endpoint, checked September 15. A zero result describes this indexed query only, not worldwide nonapproval or every FDA document.

0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

products.active_ingredients.name:"IPAMORELIN" OR products.active_ingredients.name:"IPAMORELIN ACETATE"

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T08:54:12.548143+00:00 · HTTP 404 · SHA-256 57b1e7534d003e4246182162fd2469cdf038de39405056f44fc006715e5496da.

  • This query does not cover all FDA safety communications, labels, compounding proceedings or other regulatory systems.

Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

    EMA search

    Local identity matching in the pinned EMA medicines metadata feed. This feed is not every national European authorization or every agency document; orphan designation is not marketing authorization.

    0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

    Search terms, record decisions and remaining work

    Case-insensitive word-boundary matching of reviewed identity terms: ["ipamorelin", "ipamorelin acetate"]

    Source retrievals and payload pins
    • Open the source endpoint ↗

      Retrieved 2026-09-15T08:34:22.905972+00:00 · HTTP 200 · SHA-256 a947c2b8a56ac2b92ec96156843f262f5e516f83b375d6791d67a8f6dc695729.

    • Complete source-document appraisal and national European sources remain open.
    • Zero identity matches apply only to these feed fields and terms.

    Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

      EMA search

      Local identity matching in the pinned EMA documents metadata feed. This feed is not every national European authorization or every agency document; orphan designation is not marketing authorization.

      0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

      Search terms, record decisions and remaining work

      Case-insensitive word-boundary matching of reviewed identity terms: ["ipamorelin", "ipamorelin acetate"]

      Source retrievals and payload pins
      • Open the source endpoint ↗

        Retrieved 2026-09-15T08:34:29.167460+00:00 · HTTP 200 · SHA-256 c0c68d7d77783e0355cbc75bdd04772e9acc163236fc68abcd794477c4c3d439.

      • Complete source-document appraisal and national European sources remain open.
      • Zero identity matches apply only to these feed fields and terms.

      Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

        EMA search

        Local identity matching in the pinned EMA orphans metadata feed. This feed is not every national European authorization or every agency document; orphan designation is not marketing authorization.

        0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

        Search terms, record decisions and remaining work

        Case-insensitive word-boundary matching of reviewed identity terms: ["ipamorelin", "ipamorelin acetate"]

        Source retrievals and payload pins
        • Open the source endpoint ↗

          Retrieved 2026-09-15T08:34:31.262344+00:00 · HTTP 200 · SHA-256 7448bf4e77e3345b3f3fbb7062c335d2302d8ea458a246bbe8256ce48aad2806.

        • Complete source-document appraisal and national European sources remain open.
        • Zero identity matches apply only to these feed fields and terms.

        Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

          Explore status sources, recent additions, and coverage gaps

          Living status brief

          What is the current status of Ipamorelin?

          Not FDA-approved; named as an unapproved new drug in a federal enforcement case. FDA staff recommended in 2024 against adding ipamorelin or ipamorelin acetate to the 503A compounding list, and FDA lists ipamorelin acetate among substances that may present significant safety risks. Ipamorelin is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.↗↗↗↗

          The cited status sources were checked through July 22, 2026. This answer changes only through the profile’s visible version and correction history.

          Evidence present

          What records are connected here?

          Evidence lanes
          3
          Source years
          7
          Drugs@FDA applications
          0

          These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

          Latest source-dated record

          What changed most recently at a cited source?

          Literature metadata · source date May 24, 2026

          PubMed record PMID 39043357↗Added to PeptideScanner August 11, 2026

          Coverage gaps

          What remains unknown or unsupported?

          PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

          PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

          Explore the Evidence Map and record counts

          Evidence Map v1

          What kinds of records connect to Ipamorelin?

          Compare collection coverage →

          This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

          17Selected dated records
          22Connected citations
          7Populated source years2012–2026
          3/4Record lanes present

          Registered human studies

          Trial composition

          0 of 2 selected trial records include at least one phase value; 0 of 2 include a status value in the retained structured contract.

          41 public history versions connect to 2 of these trial records across 7 submitted years. Open the record-history collection →

          1 exact source-declared trial-publication link connects selected NCT and PMID records. Open the exact graph →

          A phase value is unavailable here for 2 selected records; this is not counted as “no phase.”

          A status value is unavailable here for 2 selected records; this is not counted as a trial status.

          PubMed bibliography

          Publication composition

          1 of 14 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

          Publication typesJournal Article 1

          Bibliography fields unavailable here for 13 selected records; the records remain visible as metadata observations.

          Regulatory and publication surfaces

          What is structurally connected?

          Drugs@FDA applications
          0
          FDA Federal Register documents
          1
          DailyMed SPL versions
          0
          Canonical profile
          Published
          Profile structured data
          Published
          Linked dated records
          17

          Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

          Profile publication history and record counts
          Trial–publication links · 1

          Exact identifier graph

          1 trial-publication link for Ipamorelin

          Open the full graph →

          These links come only from structured NCT and PMID identifiers declared by PubMed or ClinicalTrials.gov. They do not summarize the publications or establish findings.

          Source records by collection · 17 dated records

          Research hub

          Explore the Ipamorelin evidence record

          Open all 17 records →
          17Dated records
          3Evidence types
          17Cited public sources
          7Source years

          Change ledger

          Recently changed for Ipamorelin

          Open all 19 events →

          PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

          Profile updated

          Ipamorelin profile

          We added a plain-language reader guide with cited answers, re-checked FDA’s ipamorelin briefing and compounding safety-risk page, and noted that HHS’s October 30, 2026 draft enforcement-discretion policy does not include ipamorelin.

          PeptideScanner change date
          November 14, 2026
          Evidence lane
          Profile
          Record added

          Federal Register notice 2024-21241

          The Federal Register published notice 2024-21241, attributed to FDA and its parent HHS department, on 2024-09-18. Its official title is “Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List; Revisions to the Withdrawn or Removed List,” and PeptideScanner's exact reviewed identity mapping connects the document to Ipamorelin.

          PeptideScanner change date
          August 21, 2026
          Cited source date
          September 18, 2024
          Evidence lane
          Regulatory

          Official-source collections

          Source records for Ipamorelin

          Open the full research atlas →

          Evidence types

          Coverage by source year

          Selected records span November 15, 2012 to May 24, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

          Continue exploring

          Profiles with overlapping source-year coverage

          Open the research atlas →

          These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

          Organizations and trial records named in cited sources

          Organizations named in cited records

          • U.S. Food and Drug Administration1
          • U.S. Department of Health and Human Services5
          Dated updates connected to this profile · 17

          Updates connected to this profile

          Open the full cross-source timeline →
          1. Literature metadata

            PubMed record PMID 39043357↗

            PeptideScanner retained PubMed bibliographic metadata for PMID 39043357 at 2026-07-30T16:20:38.933Z. PubMed recorded a metadata revision date of 2026-05-24 and an Entrez history date of 2024-07-23. PeptideScanner associated this retained record with the identity slug ipamorelin. These dates describe PubMed metadata history, not the article's original publication date.↗

          2. Literature metadata

            PubMed record PMID 25331030↗

            PeptideScanner retained PubMed bibliographic metadata for PMID 25331030 at 2026-07-30T16:20:34.456Z. PubMed recorded a metadata revision date of 2026-05-18 and an Entrez history date of 2014-10-22. PeptideScanner associated this retained record with the identity slug ipamorelin. These dates describe PubMed metadata history, not the article's original publication date.↗

          3. Regulatory

            Federal Register notice 2024-21241↗

            The Federal Register published notice 2024-21241, attributed to FDA and its parent HHS department, on 2024-09-18. Its official title is “Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List; Revisions to the Withdrawn or Removed List,” and PeptideScanner's exact reviewed identity mapping connects the document to Ipamorelin.↗

          4. Literature metadata

            The influence of ghrelin agonist ipamorelin acetate on the hypothalamic-pituitary-testicular axis in a cichlid fish, Oreochromis mossambicus.↗

            PubMed lists PMID 38996787 in Animal reproduction science as Journal Article, with publication-date metadata of 2024-07-05 (day precision). PeptideScanner associated the retained record with the identity slug ipamorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

          5. Literature metadata

            PubMed record PMID 25869809↗

            PeptideScanner retained PubMed bibliographic metadata for PMID 25869809 at 2026-07-30T20:43:08.964Z. PubMed recorded a metadata revision date of 2019-12-10 and an Entrez history date of 2015-04-15. PeptideScanner associated this retained record with the identity slug ipamorelin. These dates describe PubMed metadata history, not the article's original publication date.↗

          6. Literature metadata

            PubMed record PMID 9879640↗

            PeptideScanner retained PubMed bibliographic metadata for PMID 9879640 at 2026-07-30T20:46:59.653Z. PubMed recorded a metadata revision date of 2019-09-09 and an Entrez history date of 1999-01-08. PeptideScanner associated this retained record with the identity slug ipamorelin. These dates describe PubMed metadata history, not the article's original publication date.↗

          7. Literature metadata

            PubMed record PMID 9849822↗

            PeptideScanner retained PubMed bibliographic metadata for PMID 9849822 at 2026-07-30T20:46:59.652Z. PubMed recorded a metadata revision date of 2019-09-05 and an Entrez history date of 1998-12-16. PeptideScanner associated this retained record with the identity slug ipamorelin. These dates describe PubMed metadata history, not the article's original publication date.↗

          8. Literature metadata

            PubMed record PMID 11459660↗

            PeptideScanner retained PubMed bibliographic metadata for PMID 11459660 at 2026-07-30T20:48:24.201Z. PubMed recorded a metadata revision date of 2019-08-19 and an Entrez history date of 2001-07-19. PeptideScanner associated this retained record with the identity slug ipamorelin. These dates describe PubMed metadata history, not the article's original publication date.↗

          9. Literature metadata

            PubMed record PMID 10496658↗

            PeptideScanner retained PubMed bibliographic metadata for PMID 10496658 at 2026-07-30T20:48:24.176Z. PubMed recorded a metadata revision date of 2019-08-18 and an Entrez history date of 1999-09-25. PeptideScanner associated this retained record with the identity slug ipamorelin. These dates describe PubMed metadata history, not the article's original publication date.↗

          10. Literature metadata

            PubMed record PMID 10828840↗

            PeptideScanner retained PubMed bibliographic metadata for PMID 10828840 at 2026-07-30T20:50:07.370Z. PubMed recorded a metadata revision date of 2019-07-09 and an Entrez history date of 2000-06-01. PeptideScanner associated this retained record with the identity slug ipamorelin. These dates describe PubMed metadata history, not the article's original publication date.↗

          11. Literature metadata

            PubMed record PMID 15665799↗

            PeptideScanner retained PubMed bibliographic metadata for PMID 15665799 at 2026-07-30T21:09:05.701Z. PubMed recorded a metadata revision date of 2018-12-17 and an Entrez history date of 2005-01-25. PeptideScanner associated this retained record with the identity slug ipamorelin. These dates describe PubMed metadata history, not the article's original publication date.↗

          12. Literature metadata

            PubMed record PMID 9733495↗

            PeptideScanner retained PubMed bibliographic metadata for PMID 9733495 at 2026-07-30T21:08:59.367Z. PubMed recorded a metadata revision date of 2018-12-01 and an Entrez history date of 1998-09-11. PeptideScanner associated this retained record with the identity slug ipamorelin. These dates describe PubMed metadata history, not the article's original publication date.↗

          Citations

          Sources

          Coverage and sources →

          Numbered markers in the text point here. Each link opens the original public record.

          1. 1
            Certain bulk drug substances for use in compounding that may present significant safety risks ↗

            U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

          2. 2
            Nicholasville Compounding Pharmacy and Its Owner Plead Guilty to Unlawful Distribution of Prescription Drugs ↗

            U.S. Department of Justice · Official source · Source checked July 22, 2026

          3. 3
            FDA evaluation of ipamorelin-related bulk substances, August 19, 2024 ↗

            U.S. Food and Drug Administration · Official source · Source checked September 15, 2026

          4. 4
            Federal Register notice 2024-21241 · published 2024-09-18 · Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List; Revisions to the Withdrawn or Removed List ↗

            Federal Register via GovInfo · Official source · Source checked August 21, 2026

          5. 5
            Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

            Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

          6. 6
            HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

            U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026